



A Clinical Stage Company Pioneering the Next Generation of Cellular Therapies

Investor Webinar

5 May 2025



Important information



Summary information

This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (**CYP**, or **Cynata**) which is current as at 2 May 2025. This Presentation should be read in conjunction with CYP's other periodic and continuous disclosure information lodged with the Australian Securities Exchange (**ASX**), which are available at www.asx.com.au.

Not an offer

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment advice

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities.

Investment risk and past performance

An investment in CYP securities is subject to known and unknown risks, some of which are beyond the control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP performance including future share price performance.

Financial data

All financial information in this Presentation is in Australian currency (A\$) unless otherwise stated. This Presentation contains historical financial information based on financial information that has been disclosed to the ASX. Any discrepancies between totals and sums of components in tables and figures in this Presentation are due to rounding.

Forward-looking statements

This Presentation contains certain 'forward looking statements', which can generally be identified by the use of forward looking words such as 'expect', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance', 'potential' and other similar expressions. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of CYP, its directors and management, and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements.

Industry and Market data

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither CYP nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications.

Disclaimer

To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (**Related Persons**) exclude and disclaim all liability, including without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice.

Corporate overview



Cynata Therapeutics Limited (ASX:CYP)

- Clinical stage biotechnology company, headquartered in Melbourne, Australia
- Commercialising the novel Cymerus™ iPSC¹-based platform
- Scalable and consistent production of potent cell-based therapies for a range of serious medical disorders

Financial information

Share price (2 May 2025)	A\$0.195
Shares on issue	~225m
Market capitalisation	~A\$44m
Cash ²	~ A\$8.5m

¹ iPSC = induced Pluripotent Stem Cell
² As at 31 March 2025

Largest shareholders



10.3%



10.0%




3.6%

Top 20 shareholders hold ~47% of shares on issue

Share price performance




Clinical pipeline



Note: Cynata retains commercial rights for both of the partner funded & managed programs



March 2025 Quarter – Key Highlights



Phase 2 clinical trial in aGvHD

- Trial ongoing at >35 clinical centres in Australia, USA, EU and Turkey
- Patient enrolment has progressed very well in recent months; now >60% complete
- Completion of enrolment anticipated ~Jul 2025
- Primary results (after 100 days' follow-up) still anticipated late 2025

Phase 3 clinical trial in osteoarthritis

- Patient enrolment completed in Nov 2023
- Patient treatment completed in Nov 2024
- Last patient visit expected in Nov 2025
- Results expected H1 2026



Phase 1 clinical trial in kidney transplantation

- First patient received CYP-001 in Dec 2024
- Patient enrolment continues; Cohort 1 completion expected during the currently ongoing quarter

Further scientific validation

- Paper underlining strengths of Cymerus™ platform published in *npj Regenerative Medicine*, a leading peer-reviewed journal published by *Nature Portfolio*
- Key findings:
 - Effects of MSCs largely driven by *secretomes* (proteins and other molecules released by cells)
 - Cymerus MSC secretomes contained many more unique proteins and showed greater immunomodulatory effects than secretomes of donor-tissue derived MSCs
 - Secretomes of iPSC-derived and umbilical cord-derived MSCs resulted in significantly faster wound closure than bone marrow or adipose tissue-derived MSCs



Reminder – DFU Phase 1 trial results

Diabetes fastest growing disease worldwide¹

Est. 38 million Americans have diabetes²


Up to 34% of those with diabetes will develop a foot ulcer³

More than 15% of foot ulcers result in **amputation** of the foot or limb³


150,000+ lower extremity amputations **per year** in the US following **chronic DFU**⁴

Estimated annual costs to US public and private payers: **US\$9–13 billion**⁵

Mean change in wound surface area (all wounds)



Larger wounds measuring >200 mm²




These results are highly encouraging when compared with the results achieved using current standard of care (SOC)

1. Hossain et al. Health Sci Rep. 7(3):e2004 (2024).
2. American Diabetes Association: <https://diabetes.org/about-diabetes/statistics/about-diabetes>
3. McDermott et al. Diabetes Care. 46:209–221 (2023).

4. American Diabetes Association: <https://diabetes.org/advocacy/amputation-prevention-alliance>
5. Raghav et al. Ther Adv Endocrinol Metab. 9(1) 29-31 (2018).
For further information on the Phase 1 clinical trial: <https://clinicaltrials.gov/study/NCT05165628>



Outlook and commercial potential



Industry connections



- We are continuing to progress partnering discussions with various partners, regarding various assets
- Upcoming catalysts will accelerate and broaden partnering discussions
- We continue to attend leading conferences in our sector, to tell our story and open new discussion



JP Morgan BioWeek/Biotech Showcase
San Francisco, January 2025

Company presentation,
partnering meetings



Advanced Therapies Congress
London, March 2025

Company presentation,
partnering meetings



International Society of Cell and Gene Therapy
New Orleans, May 2025

Invited speaker,
partnering meetings



International Society of Stem Cell Research
Hong Kong, June 2025

Invited speaker




BIO International
Boston, June 2025

Partnering meetings

Upcoming catalysts*



DFU results announced Dec 2024; results from **three** further trials expected by 1H 2026



* Timing of events is approximate, based on the Company's information as at the date of this presentation, and subject to change



Cynata Therapeutics Ltd
Level 3, 100 Cubitt Street
Cremorne, Victoria 3121, Australia



info@cynata.com



www.cynata.com

